HRP20210720T1 - Osnovni hemihidrat bez acetamida n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil], postupci proizvodnje i njegove uporabe - Google Patents
Osnovni hemihidrat bez acetamida n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil], postupci proizvodnje i njegove uporabe Download PDFInfo
- Publication number
- HRP20210720T1 HRP20210720T1 HRP20210720TT HRP20210720T HRP20210720T1 HR P20210720 T1 HRP20210720 T1 HR P20210720T1 HR P20210720T T HRP20210720T T HR P20210720TT HR P20210720 T HRP20210720 T HR P20210720T HR P20210720 T1 HRP20210720 T1 HR P20210720T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- phenyl
- thiazol
- pyridinyl
- acetamide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 238000004519 manufacturing process Methods 0.000 title claims 2
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 title 1
- 239000012458 free base Substances 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 238000002156 mixing Methods 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims 1
- RIDNBUBZBRPJEY-UHFFFAOYSA-N 4-amino-1,3-thiazole-2-sulfonic acid Chemical compound NC=1N=C(SC1)S(=O)(=O)O RIDNBUBZBRPJEY-UHFFFAOYSA-N 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 208000001688 Herpes Genitalis Diseases 0.000 claims 1
- 208000004898 Herpes Labialis Diseases 0.000 claims 1
- 206010019973 Herpes virus infection Diseases 0.000 claims 1
- 208000006142 Infectious Encephalitis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010067152 Oral herpes Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- DZNBZPKZOBDXEL-UHFFFAOYSA-N dicyclohexyl-(2-dicyclohexylphosphanylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)P(C1CCCCC1)C1CCCCC1)C1CCCCC1 DZNBZPKZOBDXEL-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004946 genital herpes Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] s molekularnom formulom C18H18N4O3S2 x 0.5 H2O.
2. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] prema zahtjevu 1, koji sadrži vrhove XRPD na 5.9, 11.7, 15.5 i 18.7.
3. Farmaceutski pripravak koji sadrži osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] prema bilo kojem od prethodnih zahtjeva, naznačen time što navedeni pripravak nadalje sadrži najmanje jedan farmaceutski prihvatljiv ekscipijent.
4. Farmaceutski pripravak koji se može dobiti formuliranjem osnovnog hemihidrata bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] kako je definiran u bilo kojem od prethodnih zahtjeva 1 i 2 s najmanje jednim farmaceutski prihvatljivim ekscipijentom.
5. Farmaceutski pripravak kako je definiran u bilo kojem od zahtjeva 3 i 4, naznačen time što je osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] prisutan u količini od oko 0.1 do oko 10% m/m.
6. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] prema bilo kojem od zahtjeva 1 i 2 za uporabu kao lijek.
7. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] kako je definirano u bilo kojem od zahtjeva 1 i 2 za uporabu u liječenju i/ili prevenciji infekcija virusom herpes.
8. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] kako je definirano u bilo kojem od zahtjeva 1 i 2 za uporabu u liječenju i/ili prevenciji infekcija virusom herpes, pri čemu su navedeni virusi herpesa odabrani iz redova simplex virusa.
9. Osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] kako je definirano u bilo kojem od zahtjeva 1 i 2 za uporabu u liječenju i/ili prevenciji infekcije virusom herpes prema zahtjevu 8 odabran je iz skupine koja obuhvaća ponavljajući herpes labialis, herpes genitalis, herpes keratitis, herpes meningitis i/ili encefalitis, i herpes infekcije kod novorođenčeta.
10. Postupak za proizvodnju osnovnog hemihidrata bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] kao što je definirano u bilo kojem od zahtjeva 1 do 2, naznačen time što navedeni postupak sadrži sljedeće korake:
a) Miješanje amida (4-piridin-2-il-fenil) -octene kiseline i aminotiazola sulfonske kiseline u N-metilpirolidonu (NMP);
b) Hlađenje mješavine dobivene u koraku a);
c) Dodavanje N-etil-N’-(3-dimetilaminopropil)-karbodiimid hidroklorida (EDC x HCl) u navedenu mješavinu dobivenu u koraku b);
d) Miješanje otopine dobivene u koraku c) i dodavanje pročišćenoj H2O;
e) Filtriranje otopine dobivene u koraku d);
f) Pranje proizvoda u formi kolača dobivenog u koraku e);
g) Sušenje proizvoda dobivenog u koraku f);
h) Dodavanje H2O otopini dobivenoj u koraku g);
i) Miješanje suspenzije dobivene u koraku h);
j) Hlađenje suspenzije dobivene u koraku i);
k) Miješanje suspenzije dobivene u koraku j);
l) Izoliranje proizvoda filtracijom suspenzije dobivene u koraku k);
m) Pranje proizvoda dobivenog u koraku l) s H2O;
n) Sušenje proizvoda dobivenog u koraku m).
11. Farmaceutski pripravak koji sadrži osnovni hemihidrat bez acetamida N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil] dobiven postupkom prema zahtjevu 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200967 | 2016-11-28 | ||
| EP17811883.2A EP3544976B1 (en) | 2016-11-28 | 2017-11-28 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof |
| PCT/EP2017/080653 WO2018096170A1 (en) | 2016-11-28 | 2017-11-28 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210720T1 true HRP20210720T1 (hr) | 2021-09-03 |
Family
ID=57421711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210720TT HRP20210720T1 (hr) | 2016-11-28 | 2021-05-07 | Osnovni hemihidrat bez acetamida n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil], postupci proizvodnje i njegove uporabe |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11021474B2 (hr) |
| EP (3) | EP4201934A1 (hr) |
| JP (2) | JP6978501B2 (hr) |
| KR (2) | KR102622289B1 (hr) |
| CN (2) | CN109996798B (hr) |
| AR (1) | AR110249A1 (hr) |
| AU (3) | AU2017365632B2 (hr) |
| CA (1) | CA3045059A1 (hr) |
| CY (1) | CY1124523T1 (hr) |
| DK (2) | DK3848369T3 (hr) |
| ES (2) | ES2941390T3 (hr) |
| HR (1) | HRP20210720T1 (hr) |
| HU (1) | HUE054703T2 (hr) |
| LT (1) | LT3544976T (hr) |
| PL (1) | PL3544976T3 (hr) |
| PT (2) | PT3544976T (hr) |
| RS (1) | RS61905B1 (hr) |
| SI (2) | SI3848369T1 (hr) |
| TW (2) | TWI811800B (hr) |
| UY (1) | UY37496A (hr) |
| WO (1) | WO2018096170A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| CN109996798B (zh) * | 2016-11-28 | 2023-05-05 | 艾库里斯有限及两合公司 | N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙酰胺游离碱半水合物、其制造方法和用途 |
| JP7316214B2 (ja) * | 2016-11-28 | 2023-07-27 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｎ－［５－（アミノスルホニル）－４－メチル－１，３－チアゾール－２－イル］－ｎ－メチル－２－［４－（２－ピリジニル）－フェニル］－アセトアミドの遊離塩基形のマレイン酸塩、医薬製剤、製造方法およびヘルペスウイルスの処置のためのその使用 |
| AR113344A1 (es) | 2017-10-05 | 2020-04-22 | Innovative Molecules Gmbh | Enantiómeros de una serie de compuestos antivirales |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| EP3925595A1 (en) * | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
| EP4096632A1 (en) * | 2020-03-26 | 2022-12-07 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
| WO2024047507A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| WO2024047506A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496820A (en) * | 1988-10-20 | 1996-03-05 | Peraelampi; Markku | Ophthalmic use of S-timolol hemihydrate |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| CN109996798B (zh) | 2016-11-28 | 2023-05-05 | 艾库里斯有限及两合公司 | N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙酰胺游离碱半水合物、其制造方法和用途 |
| JP7316214B2 (ja) * | 2016-11-28 | 2023-07-27 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｎ－［５－（アミノスルホニル）－４－メチル－１，３－チアゾール－２－イル］－ｎ－メチル－２－［４－（２－ピリジニル）－フェニル］－アセトアミドの遊離塩基形のマレイン酸塩、医薬製剤、製造方法およびヘルペスウイルスの処置のためのその使用 |
| EP4096632A1 (en) * | 2020-03-26 | 2022-12-07 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
-
2017
- 2017-11-28 CN CN201780073223.2A patent/CN109996798B/zh active Active
- 2017-11-28 US US16/464,448 patent/US11021474B2/en active Active
- 2017-11-28 HU HUE17811883A patent/HUE054703T2/hu unknown
- 2017-11-28 WO PCT/EP2017/080653 patent/WO2018096170A1/en unknown
- 2017-11-28 SI SI201731326T patent/SI3848369T1/sl unknown
- 2017-11-28 DK DK21157420.7T patent/DK3848369T3/da active
- 2017-11-28 CN CN202310418723.2A patent/CN116804007A/zh active Pending
- 2017-11-28 KR KR1020237017062A patent/KR102622289B1/ko active IP Right Grant
- 2017-11-28 CA CA3045059A patent/CA3045059A1/en active Pending
- 2017-11-28 ES ES21157420T patent/ES2941390T3/es active Active
- 2017-11-28 PT PT178118832T patent/PT3544976T/pt unknown
- 2017-11-28 PL PL17811883T patent/PL3544976T3/pl unknown
- 2017-11-28 PT PT211574207T patent/PT3848369T/pt unknown
- 2017-11-28 KR KR1020197018286A patent/KR102536156B1/ko active IP Right Grant
- 2017-11-28 ES ES17811883T patent/ES2870614T3/es active Active
- 2017-11-28 LT LTEP17811883.2T patent/LT3544976T/lt unknown
- 2017-11-28 SI SI201730749T patent/SI3544976T1/sl unknown
- 2017-11-28 EP EP22211343.3A patent/EP4201934A1/en not_active Withdrawn
- 2017-11-28 UY UY0001037496A patent/UY37496A/es unknown
- 2017-11-28 DK DK17811883.2T patent/DK3544976T3/da active
- 2017-11-28 RS RS20210576A patent/RS61905B1/sr unknown
- 2017-11-28 TW TW110135747A patent/TWI811800B/zh active
- 2017-11-28 EP EP17811883.2A patent/EP3544976B1/en active Active
- 2017-11-28 EP EP21157420.7A patent/EP3848369B1/en active Active
- 2017-11-28 TW TW106141448A patent/TWI737861B/zh active
- 2017-11-28 JP JP2019528091A patent/JP6978501B2/ja active Active
- 2017-11-28 AR ARP170103302A patent/AR110249A1/es unknown
- 2017-11-28 AU AU2017365632A patent/AU2017365632B2/en active Active
-
2021
- 2021-04-02 US US17/221,000 patent/US20210269429A1/en active Pending
- 2021-05-07 HR HRP20210720TT patent/HRP20210720T1/hr unknown
- 2021-05-13 CY CY20211100407T patent/CY1124523T1/el unknown
- 2021-08-27 AU AU2021221901A patent/AU2021221901B2/en active Active
- 2021-11-11 JP JP2021184218A patent/JP7289891B2/ja active Active
-
2022
- 2022-11-03 AU AU2022263540A patent/AU2022263540A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210720T1 (hr) | Osnovni hemihidrat bez acetamida n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil], postupci proizvodnje i njegove uporabe | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| JP2015503622A5 (hr) | ||
| CA2909742C (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| MX2016009514A (es) | Procedimiento para la preparacion de n-[(3-aminooxetan-3-il)metil] -2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazo lin-4-amina. | |
| JP2007516983A5 (hr) | ||
| HRP20210526T1 (hr) | Oksisteroli i postupci za njihovu uporabu | |
| HRP20211331T1 (hr) | Inhibitor površinskog antigena hepatitis b virusa | |
| SI1919465T1 (en) | GSK-3 INHIBITORS | |
| HRP20150056T1 (hr) | Soli clopidogrela i postupak pripreme | |
| HRP20210942T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
| JP2017504653A5 (hr) | ||
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| SI2834239T1 (en) | Heterobicyclic compounds as inhibitors of beta-lactamase | |
| JP2015503621A5 (hr) | ||
| JP2019513804A5 (hr) | ||
| JP2018516904A5 (hr) | ||
| JP2017523169A5 (hr) |